Aclaris Therapeutics (ACRS) Assets Average (2015 - 2026)

Aclaris Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• On a quarterly basis, Assets Average fell 14.16% year-over-year to $179.6 million in Q1 2026; TTM through Mar 2026 was $179.6 million, a 14.16% decrease from a year earlier, with the FY2025 full-year figure at $190.4 million, down 8.84% from the prior year.
• Assets Average advanced to $179.6 million in Q1 2026 per ACRS's latest filing, from $168.0 million in the prior quarter.
• Across five years, Assets Average topped out at $272.8 million in Q3 2022 and bottomed at $167.6 million in Q2 2024.
• The 5-year median for Assets Average is $207.9 million (2023), against an average of $211.4 million.
• Across the five-year window, Assets Average soared 105.76% in 2022 and dropped 27.98% in 2024, its largest moves.
• Year by year, Assets Average stood at $261.1 million in 2022, then slipped by 20.39% to $207.9 million in 2023, then declined by 3.14% to $201.4 million in 2024, then dropped by 16.57% to $168.0 million in 2025, then increased by 6.9% to $179.6 million in 2026.
• Per Business Quant, the three latest ACRS Assets Average figures stand at $179.6 million (Q1 2026), $168.0 million (Q4 2025), and $182.3 million (Q3 2025).